ArticleACR open rheumatology2026
The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review.
Article in ACR open rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review documents the current status of extracorporeal membrane oxygenation (ECMO) use in patients with complications of rheumatologic diseases.
methodsFollowing Preferred Reporting Items for Systematic Reviews and Meta Analyses 2020 guidelines, we conducted a systematic review of studies published from January 2019 to February 2025. Eligible studies included patients with rheumatologic disease complications who received ECMO and had reported outcomes. Exclusion criteria included non-English publications, secondary sources, editorials, and ECMO for nonrheumatologic indications. Searches were performed in February 2025 of four different databases: MEDLINE, Embase+Embase Classic (via Ovid), Scopus, and Web of Science (Core Collection). Data extracted included patient demographics, ECMO indications and details, therapy outcomes, and complications. Descriptive statistics were applied, and risk of bias was assessed using the Newcastle-Ottawa scale.
resultsFrom 4 different databases, 2,695 records were identified. 144 studies met inclusion criteria, comprising 734 patients. Mean age was 32.2 years (range 7 weeks-70 years), with 340 (46%) females. Common ECMO indications included diffuse alveolar hemorrhage, interstitial lung disease, myocarditis, cardiac arrest, and pulmonary embolism. Leading rheumatologic diagnoses were antineutrophil cytoplasmic antibody-associated vasculitis, inflammatory myositis, systemic lupus erythematosus, antiglomerular basement membrane disease, and antiphospholipid syndrome. ECMO successfully bridged 362 patients to recovery and 54 to transplant; 304 died, and 3 remained on ECMO.
conclusionECMO remains a potential option in life-threatening rheumatologic disease complications. In this review, 416 patients recovered due to ECMO who likely would not have otherwise survived. However, available evidence is largely limited to case reports and small retrospective studies. Limitations include small sample sizes and heterogeneity in reported data.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.